Lee's picks up China rights to Dilafor's tafoxiparin
This article was originally published in Scrip
Lee's Pharmaceutical Holdings has added to its list of licensing partners through an agreement with the private Swedish drug development firm Dilafor for Chinese rights to tafoxiparin.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.